Oxacillin Sodium
FDA-approved product (capsule, oral), marketed as Bactocill, Bactocill In Plastic Container, Oxacillin Sodium and 1 more.
- Registered studies
- 50+
- Lab records
- 22
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Bacterial disease
- Infection
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Beta-lactamase resistant penicillins
- Anti-infective classification
- Classified as an existing antimicrobial.WHO ATC J01CF04
Repurposing investigation
Oxacillin Sodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.
AI-predicted activity
AI prediction · nothing measured- MRSA9.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- E. coli32.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae46.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- M. tuberculosis39.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
- MRSA: measured active in 9 of 22 lab records
Show the 22 laboratory records, with sources
Loading records…
“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Oxacillin Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- PimozideExisting use: Psychosis, Tics, Tourette syndrome55.1% AI-predicted activityagainst E. coli15 registered studies
- VenetoclaxExisting use: Cancer, Chronic lymphocytic leukemia, Neoplasm55.0% AI-predicted activityagainst E. coli50+ registered studies
- RepotrectinibExisting use: Cancer, Neoplasm55.0% AI-predicted activityagainst E. coli17 registered studies
- Telotristat EtiprateExisting use: Carcinoid tumor, Diarrhea, Neuroendocrine neoplasm54.9% AI-predicted activityagainst E. coli27 registered studies
- Prasugrel HydrochlorideExisting use: Acute coronary syndrome, Hemorrhage, Intermediate coronary syndrome and 1 more54.8% AI-predicted activityagainst E. coli50+ registered studies
- Bosutinib MonohydrateExisting use: Chronic myelogenous leukemia, Myeloid leukemia54.6% AI-predicted activityagainst E. coli2 registered studies
- Ribociclib SuccinateExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 1 more54.5% AI-predicted activityagainst E. coli1 registered study
- Ergoloid MesylatesExisting use: Cardiovascular disease54.5% AI-predicted activityagainst E. coli2 registered studies
- CabotegravirExisting use: HIV infection, HIV-1 infection, Viral disease54.4% AI-predicted activityagainst E. coli50+ registered studies
- RisperidoneExisting use: Aggressive behavior, Autism, Bipolar disorder and 4 more54.2% AI-predicted activityagainst E. coli50+ registered studies
- LorlatinibExisting use: Cancer, Lymphoma, Neoplasm and 1 more54.1% AI-predicted activityagainst E. coli50+ registered studies
- TelaprevirExisting use: Chronic hepatitis C virus infection, Viral disease53.9% AI-predicted activityagainst E. coli50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Staphylococcus Aureus Bacteremia Antibiotic Treatment Options
NCT01792804 · start 2013-12
Registered record
- Registry ID
- NCT01792804
- Conditions
- Staphylococcus Aureus Infection
- Interventions
- Trimethoprim-Sulfamethoxazole; Clindamycin; Linezolid; Flucloxacillin; Cloxacillin; Vancomycin; Daptomycin; Cefazolin
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2013-12
- Completion
- 2020-03-26
- Enrolment
- 215
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionStaphylococcus Aureus InfectionInterventionTrimethoprim-Sulfamethoxazole; Clindamycin; Linezolid; Flucloxacillin +4 morePhasePhase 3Registry statusCompletedAdjunctive Clindamycin for Cellulitis: C4C Trial.
NCT01876628 · start 2013-10
Registered record
- Registry ID
- NCT01876628
- Conditions
- Cellulitis
- Interventions
- Flucloxacillin; Clindamycin; Placebo oral capsule
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2013-10
- Completion
- 2016-03
- Enrolment
- 410
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCellulitisInterventionFlucloxacillin; Clindamycin; Placebo oral capsulePhasePhase 4Registry statusCompletedEfficacy of a Short-term Sequential Therapy in Non-complicated Catheter Related Bacteremia by Methicillin- Susceptible S.Aureus.
NCT01875263 · start 2013-05
Registered record
- Registry ID
- NCT01875263
- Conditions
- Staphylococcus
- Interventions
- Cloxacilin; Cloxacillin; Levofloxacin
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Terminated
- Start
- 2013-05
- Completion
- 2014-11
- Enrolment
- 1
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionStaphylococcusInterventionCloxacilin; Cloxacillin; LevofloxacinPhasePhase 3Registry statusTerminatedTreatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection
NCT01191840 · start 2011-02
Registered record
- Registry ID
- NCT01191840
- Conditions
- Bacteremia
- Interventions
- Vancomycin; Vancomycin
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2011-02
- Completion
- 2017-03-04
- Enrolment
- 509
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBacteremiaInterventionVancomycin; VancomycinPhasePhase 2Registry statusCompletedStudy of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment
NCT01104662 · start 2010-04-19
Registered record
- Registry ID
- NCT01104662
- Conditions
- Complicated Skin and Skin Structure Infections; S. Aureus Bacteremia; Renal Impairment
- Interventions
- Vancomycin; Daptomycin; Semi-Synthetic Penicillin
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Terminated
- Start
- 2010-04-19
- Completion
- 2012-06-12
- Enrolment
- 92
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionComplicated Skin and Skin Structure Infections; S. Aureus Bacteremia; Renal ImpairmentInterventionVancomycin; Daptomycin; Semi-Synthetic PenicillinPhasePhase 4Registry statusTerminatedStudy to Compare Efficacy and Safety of Daptomycin in Elderly Patients With Complicated Skin and Soft Tissue Infections
NCT01184872 · start 2010-03
Registered record
- Registry ID
- NCT01184872
- Conditions
- Infections
- Interventions
- Daptomycin; Vancomycin or Semi-Synthetic Penicillins (SSPs)
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2010-03
- Completion
- 2011-03
- Enrolment
- 120
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInfectionsInterventionDaptomycin; Vancomycin or Semi-Synthetic Penicillins (SSPs)PhasePhase 3Registry statusCompletedSafety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure Infections
NCT00711802 · start 2008-07-23
Registered record
- Registry ID
- NCT00711802
- Conditions
- Skin Diseases, Infectious
- Interventions
- Daptomycin; Standard of Care (SOC)
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2008-07-23
- Completion
- 2013-10-11
- Enrolment
- 396
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSkin Diseases, InfectiousInterventionDaptomycin; Standard of Care (SOC)PhasePhase 4Registry statusCompletedUse of Probiotic Lactobacilli for the Treatment of Lactational Mastitis
NCT00716183 · start 2008-07
Registered record
- Registry ID
- NCT00716183
- Conditions
- Mastitis
- Interventions
- Lactobacillus salivarius HN6; Lactobacillus reuteri CR20; Lactobacillus fermentum LC40; Beta-lactam antibiotic
- Study type
- INTERVENTIONAL
- Phase
- Phase 2 / Phase 3
- Registry status
- Completed
- Start
- 2008-07
- Completion
- 2009-05
- Enrolment
- 300
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMastitisInterventionLactobacillus salivarius HN6; Lactobacillus reuteri CR20; Lactobacillus fermentum LC40; Beta-lactam antibioticPhasePhase 2 / Phase 3Registry statusCompletedCloxacillin as Prevention of Double Lumen Infection in Hemodialysis Patients
NCT00885300 · start 2008-01
Registered record
- Registry ID
- NCT00885300
- Conditions
- Double Lumen Infection; Hemodialysis
- Interventions
- cloxacillin; heparin
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2008-01
- Completion
- 2008-09
- Enrolment
- 100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDouble Lumen Infection; HemodialysisInterventioncloxacillin; heparinPhaseNot applicableRegistry statusCompletedStudy of Daptomycin in Subjects Undergoing Surgery for Osteomyelitis Associated With an Infected Prosthetic Caused by Staphylococci
NCT00428844 · start 2007-06-26
Registered record
- Registry ID
- NCT00428844
- Conditions
- Osteomyelitis
- Interventions
- daptomycin; daptomycin; vancomycin; teicoplanin; nafcillin; oxacillin; flucloxacillin
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2007-06-26
- Completion
- 2010-06-23
- Enrolment
- 75
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOsteomyelitisInterventiondaptomycin; daptomycin; vancomycin; teicoplanin +3 morePhasePhase 2Registry statusCompletedStaphylococcus Aureus Carriers Students Nursing Oxacillin Resistant
NCT00518076 · start 2006-09
Registered record
- Registry ID
- NCT00518076
- Conditions
- Staphylococcal Infections
- Interventions
- Not recorded
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Unknown
- Start
- 2006-09
- Completion
- Not recorded
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionStaphylococcal InfectionsInterventionNot recordedPhaseNot recordedRegistry statusUnknownComparison Between Amoxycillin/Clavulanic Acid and Oxacillin/Ceftriaxone for Community Acquired-pneumonia
NCT01166932 · start 2005-04
Registered record
- Registry ID
- NCT01166932
- Conditions
- Community-Acquired Pneumonia
- Interventions
- Amoxycillin/clavulanic acid; ceftriaxone/oxacillin
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2005-04
- Completion
- 2009-04
- Enrolment
- 104
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCommunity-Acquired PneumoniaInterventionAmoxycillin/clavulanic acid; ceftriaxone/oxacillinPhasePhase 4Registry statusCompletedBioavailability Of Flucloxacillin Capsules (250 mg and 500 mg)
NCT00358371 · start 2005-01-06
Registered record
- Registry ID
- NCT00358371
- Conditions
- Infections, Bacterial
- Interventions
- flucloxacillin 250 mg; flucloxacillin 500 mg
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2005-01-06
- Completion
- 2005-02-08
- Enrolment
- 24
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInfections, BacterialInterventionflucloxacillin 250 mg; flucloxacillin 500 mgPhasePhase 1Registry statusCompletedPhase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)
NCT00077675 · start 2004-02
Registered record
- Registry ID
- NCT00077675
- Conditions
- Infections, Gram-positive Bacterial
- Interventions
- Telavancin; vancomycin or antistaphylococcal penicillin
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2004-02
- Completion
- 2004-09
- Enrolment
- 201
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInfections, Gram-positive BacterialInterventionTelavancin; vancomycin or antistaphylococcal penicillinPhasePhase 2Registry statusCompletedDeterminants of Warfarin Metabolism
NCT00162474 · start 2003-09
Registered record
- Registry ID
- NCT00162474
- Conditions
- Healthy
- Interventions
- Warfarin; Phenytoin; Losartan & Hydrochlorothiazide; Flurbiprofen; Siponimod; Dicloxacillin
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Recruiting
- Start
- 2003-09
- Completion
- 2030-12
- Enrolment
- 1,000
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionWarfarin; Phenytoin; Losartan & Hydrochlorothiazide; Flurbiprofen +2 morePhaseNot applicableRegistry statusRecruiting